BCL2 and acute myeloid leukemia: Among them, BCL2 inhibitor venetoclax, combined with hypomethylating agents, was initially approved by the U.S. Food and Drug Administration (FDA) in November 2018, for the treatment of patients with AML who are older or unfit for intensive chemotherapy [48].